

O I P E
OCT 12 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number

10/526,905

Filing Date

February 23, 2006

First Named Inventor

Colin Watts

Art Unit

1634

Examiner Name

Stephen Thomas Kapushoc

Attorney Docket Number

FBR0002-100

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/526,905
Filing Date	February 23, 2006
First Named Inventor	Colin Watts
Art Unit	1634
Examiner Name	Stephen Thomas Kapushoc
Attorney Docket Number	FBR0002-100

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AD	Bahassi et al., "Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways," <i>Oncogene</i> (2002) 21:6633-6640.	
	AE	Callaghan et al., "Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs," <i>Oncogene</i> (1998) 17:3479-3491.	
	AF	Clancy, Jennifer et al., "EDD, The Human Hyperplastic Discs Gene, Is Amplified ? Overexpressed in Cancer," <i>Oncogene</i> , (2003), vo. 22, no.32, pp.5070-5081.	
	AG	Forozan et al., "Molecular cytogenetic analysis of 11 new breast cancer cell lines," <i>British Journal of Cancer</i> , (1999) 81(8):1328-1334.	
	AH	Fourth Peter MacCallum Institute Symposium "Molecular & Cell Biology of Cancer" Melbourne, Australia, November 8, 2001.	
	AI	Henderson et al., "EDD, the Human Hyperplastic Discs Protein, Has a Role in Progesterone Receptor Coactivation and Potential Involvement in DNA Damage Response," <i>The Journal of Biological Chemistry</i> (2002) 277 (29): 26468-26478.	
	AJ	Honda et al., "Cooperation of HECT-domain Ubiquitin Ligase hHYD and DNA Topoisomerase II-binding Protein for DNA Damage Response," <i>The Journal of Biological Chemistry</i> (2002) 277 (5):3599-3605.	
	AK	Huibregtse et al., "A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase," <i>Proc. Natl. Acad. Sci. USA</i> (1995) 92:2563-2567.	
	AL	Larramendy et al., "Comparative Genomic Hybridization Reveals Complex Genetic Changes in Primary Breast Cancer Tumors and Their Cell Lines," <i>Cancer Genet Cytogenet</i> (2000) 119:132-138.	
	AM	Mansfield et al., "Genetic and Molecular Analysis of hyperplastic discs, a Gene Whose Product Is Required for Regulation of Cell Proliferation in Drosophila melanogaster Imaginal Discs and Germ Cells," <i>Developmental Biology</i> (1994) 165:507-526.	
	AN	Muller et al., "Molecular characterization of a novel rat protein structurally related to poly(A) binding proteins and the 70K protein of the U1 small nuclear ribonucleoprotein particle (snRNP)," <i>Nucleic Acids Research</i> (1992) 20 (7):1471-1475.	
	AO	Richter et al., "Chromosomal Imbalances Are Associated with a High Risk of Progression in Early Invasive (pT1) Urinary Bladder Cancer," <i>Cancer Research</i> (1999) 59:5687-5691.	
	AP	Saunders et al., "Embryonic lethality in mice with a targeted disruption of EDD, the homologue of the Drosophila melanogaster tumour suppressor gene Hyd," <i>Cancer Research Program, Garvin Institute of Medical Research, Australia</i> , November 8, 2001.	
	AQ	Tosi et al., "Characterization of the Human Myeloid Leukemia-Derived Cell Line GF-D8 by Multiplex Fluorescence In Situ Hybridization, Subtelomeric Probes, and Comparative Genomic Hybridization," <i>Genes, Chromosomes & Cancer</i> (1999) 24:213-221.	
		ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/	

Examiner
Signature

/Mark Halvorson/

Date
Considered

07/25/2008